



Catalyst Pharmaceuticals, Inc.  
Investor Relations Department  
355 Alhambra Circle  
Suite 1250  
Coral Gables, FL 33134  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

#### NASDAQ: CPRX <sup>1</sup>

Last Trade:	3.11
Trade Time:	1:49 PM ET 11/20/17
Change:	0.18  (6.181%)
Day Range	2.95 - 3.12
52-Week Range	1.01 - 3.24
Volume	1,740,834
Market Cap. (\$M)	265.151
Shares Out (M)	85.230


<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Catalyst Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder. Catalyst's lead candidate, amifampridine phosphate, for the treatment of LEMS has completed testing in a global, multi-center, double-blinded randomized pivotal Phase 3 trial resulting in positive top-line data. Catalyst has recently filed an NDA for this product seeking approval for its use as a treatment of LEMS and Congenital Myasthenic Syndromes (CMS). Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder, and movement disorders associated with the treatment of Parkinson's Disease.

... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- 11/08/17 [Catalyst Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides Corporate Update](#)
- 11/01/17 [Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9th, 2017](#)
- 10/31/17 [Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome](#)
- 10/16/17 [Catalyst Pharmaceuticals to Present at 16th Annual BIO Investor Forum](#)
- 08/30/17 [Catalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities](#)

### Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

### Financials [\[ View all \]](#)

- 03/15/17 [Annual Report \(10-K\)](#)
- 04/14/17 [Definitive Proxy Statement](#)
- 11/08/17 [Quarterly Report \(10-Q\)](#)
- 08/09/17 [Quarterly Report \(10-Q\)](#)
- 05/10/17 [Quarterly Report \(10-Q\)](#)